PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
-
PROTACs Related Products (1398)
Related Products (1398)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
PROTAC BRD4 Degrader-22
0 ImagesCat. No.: HY-155393CAS No.: 3032850-37-3
-
Hyp-dBET1
0 ImagesCat. No.: HY-173256Hyp-dBET1 is a hypoxia-activated BRD4 PROTAC degrader. The IC50 of Hyp-dBET1 for reducing cell viability under hypoxic conditions is approximately 153 nM to 192 nM, while it shows low activity under normoxic conditions (IC50 of approximately 2.8 μM to 3.8 μM). Hyp-dBET1 induces BRD4 degradation under hypoxic conditions, converts to dBET1 in hypoxic environments, and downregulates the expression level of ZFP-91. Hyp-dBET1 can be used in studies related to breast cancer, cervical cancer and solid tumors.
-
VtCD-cTP-ALKF-2
0 ImagesCat. No.: HY-188197VtCD-cTP-ALKF-2 is a DAPK1 PROTAC degrader. VtCD-cTP-ALKF-2 can bind to dephosphorylated DAPK1, recruit VHL E3 ligase, and induce ubiquitin-proteasome-mediated degradation. VtCD-cTP-ALKF-2 can be used for research on Alzheimer's disease.
-
ERD-1233
0 ImagesCat. No.: HY-169367ERD-1233 is an orally active ERα PROTAC degrader with a DC50 of 0.9 nM. ERD-1233 exhibits plasma stability and microsomal stability across multiple species, and shows no significant inhibitory effect on major cytochrome P450 subtypes and hERG channels. ERD-1233 inhibits tumor growth and degrades ERα protein levels in xenograft tumor models, with favorable biosafety. ERD-1233 can be used in breast cancer-related research.
-
PROTAC SARS-CoV-2 Mpro degrader-2
0 ImagesCat. No.: HY-157805CAS No.: 3057294-32-0PROTAC SARS-CoV-2 Mpro degrader-2 is a SARS-CoV-2 Mpro PROTAC degrader with a DC50 of 1.34 μM. PROTAC SARS-CoV-2 Mpro degrader-2 recruits the VHL E3 ligase to mediate ubiquitination and proteasomal degradation of SARS-CoV-2 Mpro, without inhibiting the catalytic activity of Mpro. PROTAC SARS-CoV-2 Mpro degrader-2 exhibits anti-SARS-CoV-2 activity in infected cells, as well as broad-spectrum antiviral activity against coronaviruses including HCoV-OC43 and HCoV-229E. PROTAC SARS-CoV-2 Mpro degrader-2 can be used in studies related to SARS-CoV-2 infection, HCoV-OC43 infection, and HCoV-229E infection.
-
PROTAC PTPN2 degrader-2 TFA
0 ImagesCat. No.: HY-153938ACAS No.: 2912307-39-0
-
PZ703b hydrochloride
0 ImagesCat. No.: HY-115718BPurity: 99.18%PZ703b hydrochloride is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b hydrochloride can be used for the research of bladder cancer research.
-
PROTAC BRD4 Degrader-41
0 ImagesCat. No.: HY-179734PROTAC BRD4 Degrader-41 (Compound A5) is a BRD4 PROTAC degrader with a DC50 of 0.97 nM. PROTAC BRD4 Degrader-41 exhibits potent anti-proliferative activity against various types of cancer cells such as AML, lymphoma, breast cancer, ovarian cancer, and non-small cell lung cancer. PROTAC BRD4 Degrader-41 can induce G0/G1 phase arrest and apoptosis in MV4-11 cells. PROTAC BRD4 Degrader-41 downregulates the transcriptional level of c-Myc.
-
Gly-PEG3-BA
0 ImagesCat. No.: HY-180966CAS No.: 3057939-66-6Gly-PEG3-BA is an EML4-ALK PROTAC degrader. Gly-PEG3-BA effectively reduces EML4-ALK with a DC50 value of 0.50 μM in H3122 (EML4-ALK) cells. Gly-PEG3-BA effectively reduces EGFR mutant (L858R/T790M) levels with a DC50 of 20.15 μM in H1975 (EGER-L858R/T790M) cells. Gly-PEG3-BA exerts potent antiproliferation activity in H3122 (EML4-ALK) and H1975 (EGER-L858R/T790M) cells with IC50s value of 0.84 and 20.74 μM. Gly-PEG3-BA can be used for non-small lung cancer research.
-
PROTAC BRD4 Degrader-35
0 ImagesCat. No.: HY-177041CAS No.: 2503035-53-6
-
KB03-SLF
0 ImagesCat. No.: HY-147196CAS No.: 2384184-42-1KB03-SLF is a bifunctional PROTAC, formed by conjugating the cysteine-targeting KB03 exploratory fragment with SLF (HY-114872), an FKBP12 ligand that does not support the degradation of FKBP12NLS. KB03-SLF fails to degrade nuclear-localized FKBP12NLS in cells, nor can it mediate the interaction between DCAF16 and FKBP12NLS in a manner similar to KB02-SLF (HY-129610).
-
PROTAC HDAC6 degrader 4
0 ImagesCat. No.: HY-172359PROTAC HDAC6 degrader 4 is a potent and selective HDAC6 PROTAC degrader with an IC50 of 0.295 μM. PROTAC HDAC6 degrader 4 bridges HDAC6 and the CRBN E3 ubiquitin ligase to form a ternary complex, thereby inducing the specific degradation of HDAC6 via the ubiquitin-proteasome system. PROTAC HDAC6 degrader 4 can be used in studies related to multiple myeloma.
-
P22D
0 ImagesCat. No.: HY-180979CAS No.: 2635386-51-3P22D is a BCR-ABL PROTAC degrader based on Dasatinib (HY-10181), with a DC50 value of approximately 10 nM for the wild-type BCR-ABL protein. P22D cannot degrade the BCR-ABL T315I mutant. P22D has inhibitory activity against K562 cells (wild type), but is ineffective against BaF3-BCR-ABL (T315I) cells. P22D can be used for research on chronic myeloid leukemia and acute lymphocytic leukemia.
-
PROTAC BRD4 Degrader-39
0 ImagesCat. No.: HY-175767PROTAC BRD4 Degrader-39 is a selective targeting Bromodomain protein 4 (BRD4) degrader with an DC50 value of 24.66 nM. PROTAC BRD4 Degrader-39 conjugates BRD PROTAC (ARV-771) (HY-100972) with carbohydrate. PROTAC BRD4 Degrader-39 selectively delivers to tumor cells with high GLUT1 expression, followed by GSH-triggered release of ARV-771 and degrades BRD4. PROTAC BRD4 Degrader-39 can inhibit tumor growth and show no significant toxicity. PROTAC BRD4 Degrader-39 can be used for the research of cancer, such as breast cancer.
-
C199
0 ImagesCat. No.: HY-174445CAS No.: 3107801-96-4C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity.
